What question did this study set out to answer?

The study aims to determine the usage patterns and clinical profiles of patients treated with dapagliflozin in India.

April 8, 2026Cureus0 citationsOpen Access

Dapagliflozin-Based Therapies in Patients With Type 2 Diabetes Mellitus in an Outpatient Real-World Setting Across India: The DAPATURN Study

RCRajeev ChawlaDiabetes Foundation SKSabeer T. K.Lupin Pharmaceuticals (India)KSK. P. SinghFortis Hospital

Key Points

The study aims to determine the usage patterns and clinical profiles of patients treated with dapagliflozin in India.
Conducted an observational, cross-sectional study across 661 sites in four zones of India.
Analyzed baseline demographics and comorbidities of 34,443 enrolled patients.
Assessed usage patterns of dapagliflozin formulations, including dual and triple fixed-dose combinations.
Dapagliflozin + sitagliptin + metformin was the most common formulation (33.84%).
Mean HbA1c was 8.53% and mean body mass index was 27.21 kg/m².
Higher dapagliflozin + sitagliptin use in patients with hypertension (34.30%) and dyslipidemia (35.06%).

Abstract

Aim: Determination of usage patterns and clinical profile of patients receiving dapagliflozin and its combinations in outpatient settings across India. Methods: An observational, cross-sectional study was conducted across 661 sites in four zones of India from March to December 2024. Baseline demographics, comorbidities, and used dapagliflozin formulations (dual or triple fixed-dose combination (FDC)) were recorded to analyze usage patterns. Result: A total of 34,443 patients were enrolled from North (n = 8,035), South (n = 8,205), East (n = 11,143), and West (n = 7,060) India, with a mean age of 54.94 ± 11.35 years. Mean glycemic hemoglobin (HbA1c) and body mass index were 8.53 ± 1.56% and 27.21 ± 4.93 kg/m², respectively. The most common formulation was dapagliflozin + sitagliptin + metformin triple FDC (n = 11,657, 33.84%), followed by dapagliflozin + sitagliptin dual FDC (n = 9,940, 28.86%) and dapagliflozin + metformin dual FDC (n = 1,808, 5.24%). Dapagliflozin + sitagliptin was most used in patients with hypertension (n = 1045, 34.30%), dyslipidemia (n = 500, 35.06%), chronic kidney disorder (CKD) (n = 54, 36.99%), heart failure (HF) (n = 52, 35.86%), hypertension + dyslipidemia (n = 225, 31.91%), and atherosclerotic cardiovascular disease (ASCVD) + dyslipidemia (n = 124, 38.15%). Triple FDC use was highest in ASCVD (n = 782, 33.56%) and HF + CKD (n = 15, 50%). In both HbA1c groups (8.5%), dapagliflozin + sitagliptin (n = 6,332, 31.5%, vs. n = 3,608, 25.16%) and triple FDC dapagliflozin + sitagliptin+ metformin (n = 6,456, 32.11%, vs. n = 5,200, 36.27%) were most used. Dapagliflozin + sitagliptin use increased with diabetes duration (10 years, n = 1,422, 39.45%), while triple FDC preference remained high from <1 year (n = 637, 35.49%) to 10 years (n = 4,192, 34.96%). Conclusions: This study highlights real-world dapagliflozin use in India, showing that dapagliflozin-based FDCs are widely adopted across diverse patient groups.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Chawla et al. (Mon,) studied this question.

synapsesocial.com/papers/69d5f05d74eaea4b11a79b98 https://doi.org/https://doi.org/10.7759/cureus.106506

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI에게 질문

Bookmark

View Full Paper